Patients with coeliac disease are advised to take a strict gluten free diet, and usually avoid wheat, rye, barley, and oats. Although there is no doubt that sensitivity to gluten varies between patients'-3 and some can tolerate small amounts, strict adherence to a gluten free diet is usually strongly recommended, particularly in view of the possibility of protection from malignancy. 4 A reliable and specific means of assessing the gluten content of food would be of great benefit to patients, dietitians, food manufacturers, and gastroenterologists. In this regard there have been several recent reports of enzyme linked immunoassays to detect gluten in foods. These assays are generally sensitive, specific, and relatively easy to perform and their role in testing gluten toxicity will be reviewed here.
Windemann et al5 described an ELISA assay for wheat a gliadin and whole gliadin using polyclonal rabbit or mouse enzyme labelled antisera. This assay was very sensitive and could detect 0 4 ng a gliadin or 4 ng whole gliadin. They went on to use the assay to detect a gliadin and whole gliadin in unheated gluten containing and gluten free foods.6 There were some problems, however, since different extraction solvents had to be used for foods containing cocoa and the assays were too specific since a, P, and y gliadins only could be detected, not w gliadin. Nor did the assay react with constituents of other toxic cereals such as rye. The test was not used on cooked food. These problems make this assay unsuitable for routine use.
McKillop et all described a similar ELISA using a polyclonal rabbit antiserum. The detection limit was 3 3 ng gliadin and the assay detected other coeliac toxic cereals. There were no details of which foods were tested, however, and whether they were cooked.
Troncone et al8 developed a similar assay for gliadin, also using a rabbit polyclonal antiserum. This assay was sensitive, could detect 0-5 ng gliadin, and also reacted with avenins from oats. There were, however, positive results with rice and maize prolamins, which are not toxic to people with coeliac disease. The authors state that these crossreactions make the assay unsuitable for testing foods for coeliac patients. In a later paper, the same authors9 showed that both human and rabbit antisera crossreacted with non-toxic proteins such as wheat albumins and globulins and zeins from maize. 14 and Friis'5 are more or less equally sensitive; they are able to detect 0-75 ng and 1 ng gliadin respectively. In addition both assays are suitably specific in that they gave positive reactions with all coeliac toxic cereals and were negative for non-toxic cereals. Interestingly, Freedman et all3 found a positive reaction with wheat glutenin and Friis's with buckwheat. Although the toxicity of both these materials has yet to be definitely established in coeliac disease, the presumption is that both are non-toxic. Both authors detected low gliadin-like reactivity in so called gluten free flours based on wheat starch. They did not use their assays to test cooked food; Friis's thought his assay would be unreliable in these circumstances.
The remaining assay is that described by Skerritt. "'2 This assay seems to be ideally specific in that correct positive and negative results with a variety of cereals were obtained. Skerritt's antibody was directed against epitopes in w gliadin, which is not destroyed in cooking, and the assay certainly retained its specificity when used with cooked and processed foods. He Alimentarius recommends that a gluten free product should contain less than 0-3% protein from wheat, rye, barley, or oats. With regard to wheat in particular, 40% of the protein is gliadin,'6 or 0-12%, representing 1 2 mg/g flour.
All the gluten free flours tested and found positive in the above assays were said to contain much less than this amount of gliadin; nevertheless bread baked with these flours may lead to symptomatic relapse in treated coeliac patients.'7 The availability of such sensitive immunological assays may lead therefore to a redefinition of the amount of gluten, if any, which can be allowed in a so called gluten free product.
If one of the above assays is to be recommended for routine use we conclude that the one described by Skerritt and coworkers seems to be suitable.
As already suggested, the main problem still remaining revolves around the question of gliadin toxicity as opposed to immunogenicity. This was addressed by Troncone et al to some extent in 1987.9 All the originators of the assays described allude to this problem and base their claims for specificity on the known toxicity or not of the various cereals and cereal fractions. We maintain, however, that the onus must be on those who report these immunological methods for detecting gliadin-like material to show, preferably by in vivo but at least by in vitro methods, that the material they are detecting is both necessary and sufficient for toxicity in patients with coeliac disease.
